Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Shares Purchased by Amundi

Amundi boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 193.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 19,583 shares of the company's stock after acquiring an additional 12,899 shares during the period. Amundi's holdings in Amphastar Pharmaceuticals were worth $717,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in AMPH. GSA Capital Partners LLP purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth about $303,000. Victory Capital Management Inc. grew its holdings in shares of Amphastar Pharmaceuticals by 10.9% during the third quarter. Victory Capital Management Inc. now owns 218,531 shares of the company's stock worth $10,605,000 after buying an additional 21,530 shares in the last quarter. Quest Partners LLC grew its holdings in shares of Amphastar Pharmaceuticals by 74.4% during the third quarter. Quest Partners LLC now owns 7,586 shares of the company's stock worth $368,000 after buying an additional 3,237 shares in the last quarter. Segall Bryant & Hamill LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the third quarter worth about $921,000. Finally, Aurora Investment Counsel grew its holdings in shares of Amphastar Pharmaceuticals by 0.4% during the third quarter. Aurora Investment Counsel now owns 54,698 shares of the company's stock worth $2,654,000 after buying an additional 232 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Separately, Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a report on Friday.

Amphastar Pharmaceuticals Trading Up 1.4 %

Amphastar Pharmaceuticals stock traded up $0.38 during trading on Friday, reaching $28.29. The company had a trading volume of 1,478,691 shares, compared to its average volume of 426,731. Amphastar Pharmaceuticals, Inc. has a 12-month low of $25.89 and a 12-month high of $53.96. The stock's 50 day moving average price is $31.91 and its two-hundred day moving average price is $40.52. The firm has a market capitalization of $1.35 billion, a price-to-earnings ratio of 9.43, a PEG ratio of 2.19 and a beta of 0.77. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43.

Insider Activity at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 4,231 shares of the business's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $27.54, for a total value of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. The trade was a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.10% of the stock is owned by insiders.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.